Form 8-K - Current report:
SEC Accession No. 0001213900-24-102857
Filing Date
2024-11-26
Accepted
2024-11-26 16:30:08
Documents
16
Period of Report
2024-11-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0222609-8k_nkgen.htm   iXBRL 8-K 34452
2 PRESS RELEASE DATED NOVEMBER 26, 2024 ea022260901ex99-1_nkgen.htm EX-99.1 12694
7 GRAPHIC ex99-1_001.jpg GRAPHIC 1967
  Complete submission text file 0001213900-24-102857.txt   275908

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nkgn-20241120.xsd EX-101.SCH 3882
4 XBRL DEFINITION FILE nkgn-20241120_def.xml EX-101.DEF 26779
5 XBRL LABEL FILE nkgn-20241120_lab.xml EX-101.LAB 37008
6 XBRL PRESENTATION FILE nkgn-20241120_pre.xml EX-101.PRE 25403
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0222609-8k_nkgen_htm.xml XML 6001
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 241504370
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)